Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck

NCT02479178 is registered in ClinicalTrials.gov with BIND Therapeutics as lead sponsor.

NCT NCT02479178
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02479178 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Lead sponsor
BIND Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2015
Completion date
January 31, 2020
Enrollment
73 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, cholangiocarcinoma, squamous cell carcinoma of head and neck, urothelial carcinoma